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Abstract
Background: Menstrually-related headache and headaches associated with oestrogen withdrawal are common
conditions, whose pathophysiology has not been completely elucidated. In this study we evaluated the influence of
combined hormonal contraceptives (CHC) on pain threshold in women presenting migraine attacks during
hormone-free interval.
Findings: Eleven women with migraine attacks recurring exclusively during the oestrogen-withdrawal period were
studied with the nociceptive flexion reflex, a neurophysiological assessment of the pain control systems, during the
third week of active treatment and during the hormone-free interval.
During the hormone-free interval, nociceptive withdrawal reflex threshold was significantly lower (12.8 ± 8.0 mA) as
compared to the third week of hormonal treatment (15.6 ± 6.6 mA) (p = 0.02). No change was observed in the pain
perceived and in the temporal summation.
Conclusions: Oestrogen withdrawal may mediate an increased sensitivity to somatosensory stimuli in women with
migraine attacks recurring during the hormone-free interval.
Keywords: Oestrogen withdrawal headache, Menstrually related migraine, Combined hormonal contraceptives,
Nociceptive withdrawal reflex
Introduction
Migraine is a common and disabling condition mostly
affecting women during fertile age; reproductive mile-
stones, as well as hormonal fluctuations across menstrual
cycle and exogenous hormonal interventions hugely influ-
ence migraine clinical course in women. In observational
studies, up to 60 % of migrainous women reported an as-
sociation between menstruation and migraine attacks,
often described as more severe, longer lasting and more
resistant to treatment than non-menstrual ones [1]. Since
a long time, oestrogen fall during late luteal phase has
been implicated as a major event triggering migraine at-
tacks [2]; oestrogen withdrawal has also been reported to
induce headache in non migrainous patients [3]; this clin-
ical entity has been codified in the International Headache
Disorders Classifications (ICHD) as oestrogen-withdrawal
hedache [4].
Events following oestrogens drop and predisposing to
headache remain to be fully elucidated. Among the
others, modulation of pain control system by sex hor-
mones has been suggested to play a role: in a previous
study, we assessed pain threshold in healthy women dur-
ing the follicular and luteal phases of spontaneous cycles
by investigating the threshold for nociceptive withdrawal
reflex triggered by electrical stimulation of the sural
nerve [5]. We observed that the pain threshold was sig-
nificantly lower during the luteal phase and this finding
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was associated with an increased perception of physical
disturbances, as assessed through the menstrual distress
questionnaire. This is likely to result from a complex
interaction between neurotransmitters and sex steroids,
whose fluctuations however cannot be easily predicted
in spontaneously menstruating women. That being so,
combined hormonal contraception (CHC) represents a
good model to study the “menstrual window” of vulner-
ability, because during the hormone-free interval the
fluctuations of exogenous hormones are sizeable and
predictable. Even though modern hormonal contracep-
tion encompasses multiple choices, the most commonly
used is “the pill” in which the hormone free interval lasts
seven days (21/7 regimens) and CHCs are discontinued
to obtain withdrawal menstrual bleeding following
21 days of use. The same is true for the patch and the
ring, which contain as well a combination of estrogen
and progestogen [6]. Because of the steep decline of
ethinyl oestradiol levels, ranging usually from 15 to
30 μg, the so-called oestrogen withdrawal symptoms
may occur and likely prevented by extended CHC regi-
mens to avoid the hormone-free interval [7].
In order to further explore the relation between
oestrogen-withdrawal and headache, in this study we eval-
uated changes in the nociceptive withdrawal reflex thresh-
old in women using CHC and reporting migraine attacks
consistently and exclusively in the hormone-free interval.
Methods
We enrolled in a pilot study 11 women who were using
CHC with a 21/7 pattern and who reported migraine at-
tacks that occurred exclusively during the hormone-free
interval of CHC in the previous 3 months. Patients ful-
filling the inclusion criteria were consecutively enrolled
among those attending the outpatient clinic of the Head-
ache Science Center of the “C. Mondino” National
Neurological Institute. The CHC formulation was oral
(20 or 30 mcg ethynil estradiol pill) in 5 patients, trans-
dermal (20 mcg ethynil estradiol patch) in 2 patients and
vaginal (15 mcg ethynil estradiol ring) in 4 patients. All
the patients followed the same therapeutic cycle with
21 days of active treatment followed by a seven-day
break (the hormone-free interval) during which with-
drawal (scheduled) bleeding occurred.
Their mean age was 30.2 ± 8.4 years (range 19–42
years). An exploratory analysis was also performed ac-
cording to the onset of headache with respect to CHC
treatment: in 5 women (mean age 30.6 ± 8.2 years) a
headache that fulfilled criteria for migraine without aura
was present prior to the exposure to CHC, while in the
other 6 women the onset of headache occurred in strict
temporal association with CHC use. It is noteworthy
that according to ICHD-III criteria beta version, patients
in the first subset received a double diagnosis (1.1
migraine without aura + 8.3.3 Oestrogen withdrawal
headache), while patients in the second subset were
diagnosed as 8.3.3 Oestrogen withdrawal headache.
Each subject was assessed twice across the same CHC
cycle: during the third week of active treatment (T0) and
during the hormone free interval (T1); all women were
headache-free at the time of testing. Nociceptive with-
drawal reflex was evaluated at the lower limb level,
through electrical stimuli delivered percutaneously at
the sural nerve; the muscular response was recorded
from the biceps femoris using an electromyografic tech-
nique. The reflex threshold following a single stimulus
(RT-SS) was considered as the lowest current intensity
needed to elicit a stable electromyografic response (mA)
(see ref. [8]). The area under the curve was also calcu-
lated (μV*ms), as an estimate of the motor units re-
cruited upon reflex trigger. Subjective pain intensity
perceived by the patient during the delivery of stimuli
with an intensity corresponding to RT-SS was rated by
participants on an 11-point scale (Visual Analogue Scale,
VAS), ranging from 0 = no pain to 10 = unbearable pain.
Temporal summation of the nociceptive flexion reflex
(RT-TS), which represents a reliable objective measure
of the functional activity of the nociceptive system in the
spinal cord, was also evaluated using train of 5 stimuli at
a frequency of 2 Hz. It was defined as the lower stimula-
tion intensity (mA) generating a clear facilitation of the
reflex response size (greater than 20 µV for 10 ms or
more) in the fourth and fifth trace during the course of
the five individual pulses train (for details see ref. [9]).
Findings
During the third week of CHC (T0), the mean RT-SS
was 15.6 ± 6.6 mA, with an average area under the EMG
track of 1287.9 ± 738.1 μV*mS, while during hormone
free interval (T1), mean RT-SS was found to be signifi-
cantly lower at 12.8 ± 8.0 mA (T1 vs T0, p = 0.02) (Fig. 1),
with a tendency toward an increase in the reflex area,
which however did not reach a statistically significant
level (p = 0.158). No change was observed in terms of
subjective pain perception at the reflex threshold as
reported by the patient through VAS (RT-VAS at T0 =
5.41 ± 2.08; RT-VAS at T1 = 5.41 ± 2.02; p = 1.00). No
differences were seen as regards temporal summation
recorded at T0 and at T1.
As far as the exploratory analysis is concerned, the
drop in reflex threshold at T1 with respect to T0 was
similar in the 2 subgroups of women: migraine onset be-
fore CHC Δ RT-SS = −18.90 ± 12.66; migraine onset after
CHC Δ RT- SS = −16.18 ± 29.31) (Fig. 2).
Discussion
Our findings indicate that the hormone-free interval of
CHC is associated to a reduction in the RT-SS of the
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lower limb nociceptive reflex in women with attacks of
migraine induced by oestrogen-withdrawal. No change
in subjective pain intensity was perceived at RT-SS from
T0 to T1, meaning that during hormone free interval,
participants rated an electrical stimulus at lower current
intensity as painful as an electrical stimulus at higher
current intensity necessary to elicit the nociceptive with-
drawal reflex during the third week of active treatment.
Thus, the objective lowering of neurophysiologically
recorded RT-SS during hormone-free intervals was indeed
coupled to an increase in the subjective self-reported pain
sensitivity.
Although not statistically significant, likely due to the
paucity of the study sample, we found a trend towards
an increase in the area under the curve at RT-SS during
the withdrawal week. This observation suggests that dur-
ing the hormone-free interval more motor units can be
recruited at RT-SS intensity. If this result is confirmed in
Fig. 1 Changes in the threshold of the nociceptive flexion reflex following a single stimulus (RT-SS) at T0 and T1 in our population. Dashed line
and dashed boxes illustrate the mean ± standard deviation of the reflex. Student’s t test for paired data (T1 vs T0, p = 0.02). Y axis: intensity of the
stimulation at RT-SS in mA
Fig. 2 Percent reduction in the nociceptive flexion reflex threshold during the suspension week in women with a positive history of migraine
(left column) and in women with a negative history of migraine attacks before the use of combined hormonal contraceptives (CHC) (right
column). Data are presented as mean ± standard error. Student’s t test for paired data, p > 0.05. Y axis: percentage reduction of RT-SS (RT-SS Δ%)
during hormone-free interval respect to baseline
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a larger sample of patients, it would strongly suggest a
role for oestrogen withdrawal in the NWR facilitation at
the spinal level.
It is noteworthy that we observed the same pattern of
neurophysiological and subjective responses in two dif-
ferent subgroups from a nosographic point of view: 1)
migraineurs whose pre-existing headache was markedly
modified by CHC as regards the temporal pattern of
occurrence of attacks and 2) healthy women whose
headache is secondary to the use of CHC. Though ob-
tained in a small sample, this finding prompts the hypoth-
esis that the observed neurophysiological similarities
between these 2 subgroups do reflect a shared patho-
physiological alteration of the nociceptive network medi-
ated by the drop in oestrogen levels. In this regard, it is
noteworthy that the working methodology in this study
was to enroll patients who shared the same migrainous
phenotype of attacks together with the same temporal pat-
tern of their occurrence.
We are aware that our study suffers some limitations
mainly represented by the small sample of patients and
the lack of a control group. We tried indeed to limit the
impact of these biases with a strict selection of patients
and with the choice of a validated neurophysiological
methodology to assess pain threshold.
Moreover, the main purpose was to validate and ex-
tend our previous observation of a reduction of the RT-
SS in healthy women during the luteal phase [5]. Taken
together, these data suggest that the decrease in
oestrogen levels makes women more ‘receptive’ to pain
as a default response. The predisposition to develop
headache or migraine attacks could be related to events
downstream of the oestrogen drop and that remain
mostly elusive. Previous studies attempted to investigate
the influence of hormonal contraceptives on pain
threshold, with conflicting results [10, 11], probably be-
cause of methodological differences. Teepker et al. [10]
in particular evaluated the pain thresholds of different
types of stimuli (heat, cold, pressure and electrical) and
found no difference between patients with or without
CHC. In agreement with our results, other authors de-
scribed fluctuations electrical pain thresholds along the
menstrual cycle [11]. A recent study that evaluated the
effect of hormonal contraception on pain sensitivity
showed that users of progestin only contraceptive have
higher pressure pain thresholds than CHC users or non-
users, thus suggesting that also progestin do play a role,
besides oestrogens, in the modulation of pain control
systems [12].
The association between migraine and oestrogens has
been widely studied and recently Chai et al. wrote a
comprehensive review on this issue [13]. In particular,
data on the effect of exogenous sex hormones showed
that oestrogens are able to modify headache patterns in
patients with migraine and that the avoidance of a
marked drop of oestrogen levels in the blood may bene-
ficial in preventing migraine occurring during estrogen
withdrawal.
Different hypotheses have been proposed to explain
the association between migraine attacks and hormonal
fluctuation. According to the “mismatch theory” [14],
a sudden oestrogen drop would result in a transient
disequilibrium between genomic and non-genomic
oestrogen-mediated actions on neurotransmission,
vascular reactivity, neuroinflammation and other sys-
tems, overall promoting neuronal activation. Among
the others, oestrogen modulation of serotonergic sys-
tem seems to play a major role in influencing pain
control system: a previous study conducted in women
presenting status migrainosus during the hormone
free interval of CHC, showed a blunted cortisol and
prolactin secretion, following a serotonergic challenge
(M-phenylchloropiperazine); moreover, the status migrai-
nosus could be prevented by transdermal estradiol supple-
mentation against placebo [15].
Conclusions
In this pilot study we described a reduction of neuro-
physiologically recorded pain threshold in women with
migraine/headache attacks during the hormone-free
interval of CHC. The drop in oestrogen levels is likely to
play a role in modulating nociception during the
hormone-free interval. Further investigations in the
neurobiological events leading to these attacks are ne-
cessary for understanding the biological aspects of CHC-
induced attacks. The observation of the same pattern in
women with or without a positive history of migraine
could be important from both a nosographic and a
therapeutic point of view.
Abbreviation
CHC, combined hormonal contraceptives; RT-SS, nociceptive withdrawal
reflex threshold elicited with a single stimulus; RT-TS, nociceptive withdrawal
reflex threshold elicited with temporal summation; VAS, visual analogue scale
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